Prostate cancer-specific anxiety in Dutch patients on active surveillance: validation of the memorial anxiety scale for prostate cancer by van den Bergh, Roderick C. N. et al.
BRIEF COMMUNICATION
Prostate cancer-speciﬁc anxiety in Dutch patients on active
surveillance: validation of the memorial anxiety scale
for prostate cancer
Roderick C. N. van den Bergh Æ Ida J. Korfage Æ
Gerard J. J. M. Borsboom Æ Ewout W. Steyerberg Æ
Marie-Louise Essink-Bot
Accepted: 11 July 2009/Published online: 9 August 2009
 The Author(s) 2009. This article is published with open access at Springerlink.com
Abstract
Purpose Men with prostate cancer (PC) may show spe-
ciﬁc disease-related anxiety. We evaluated the psycho-
metric properties of the Dutch adaptation of the Memorial
Anxiety Scale for Prostate Cancer (MAX-PC).
Methods The MAX-PC was translated using standardized
forward–backward procedures. Patients (N = 150) on
active surveillance, a strategy of initially withholding
active therapy, for recently diagnosed early PC were
mailed a questionnaire. Internal consistency was estimated
using Cronbach’s alpha. The scale structure was analyzed
using conﬁrmatory factor analysis (CFA). Construct
validity was evaluated by Pearson’s correlations between
MAX-PC scores and scores on decisional conﬂict (DCS),
generic anxiety (STAI), depression (CES-D), and general
mental health (SF-12 MCS).
Results Data from 129 respondents were used (response
rate 86%). Cronbach’s alpha for the total score and the three
subscales were 0.77, 0.91, 0.64, and 0.85, respectively. CFA
largely conﬁrmed the three-factor structure as used in the
original publication (model ﬁt: v
2 149, P = 0.051). The
patternsofdirectionsandsizesofthecorrelations(r = 0.36–
0.66) between MAX-PC scale scores and the other variables
were in accordance with a priori hypotheses, except for the
prostate-speciﬁc antigen anxiety subscale. The relatively
poor performance of this scale in the original version was
replicated.
Conclusions The structure and validity of the MAX-PC
to quantify PC-speciﬁc anxiety were largely conﬁrmed in
Dutch patients.
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Abbreviations
AS Active surveillance
CFA Conﬁrmatory factor analysis
CES-D Centre for epidemiologic studies depression
scale
DCS Decisional conﬂict scale
MAX-PC Memorial anxiety scale for prostate cancer
PRIAS Prostate cancer research international:
active surveillance
PSA Prostate-speciﬁc antigen
RMSEA Root mean square error of approximation
SF-12 MCS Short-form health-survey mental component
summary score
STAI State trait anxiety inventory
Introduction
Prostate cancer is the second largest cancer-related cause of
death in men and accounts for 16% of all cancer diagnoses,
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surveillance is a relatively new treatment strategy for men
with early prostate cancer. It consists of initially withhold-
ing radical treatment, but instead monitoring the disease and
switching to active therapy only when progression occurs.
Active surveillance may reduce overtreatment, but may
cause anxiety and distress while living with ‘untreated’
cancer.
It is important to have an instrument that adequately
measures anxiety speciﬁcally related to prostate cancer.
To assess prostate cancer-speciﬁc anxiety, Roth et al.
developed the Memorial Anxiety Scale for Prostate Cancer
(MAX-PC) [3]. They found that the MAX-PC captured
anxiety among men with prostate cancer that might be
missed using other more general anxiety measures, while,
for example, it is more strongly associated with changes in
PSA (prostate-speciﬁc antigen) level [4].
We assessed the validity of the Dutch adaptation of the
MAX-PC in Dutch men on active surveillance.
Methods
MAX-PC
The original US MAX-PC was developed for identifying
and quantifying anxiety in men with prostate cancer and
was designed for self-administration [3]. It consists of 18
items, divided into 3 subscales: ‘prostate cancer anxiety’
(11 items; example: ‘Any reference to prostate cancer
brought up strong feelings in me.’—Not at all, rarely,
sometimes, often), ‘PSA anxiety’ (3 items; example: ‘I
have been so anxious about my PSA test that I have
thought about delaying it.’—Not at all, rarely, sometimes,
often), and ‘fear of recurrence’ (4 items; example:
‘Because cancer is unpredictable, I feel I cannot plan for
the future.’—Strongly agree, agree, disagree, strongly
disagree). Total score ranges from 0 to 54, with 54 indi-
cating maximum anxiety. Scores on the 3 scales range from
0 to 33, 0 to 9, and 0 to 12, respectively. The total MAX-
PC was subdivided into the three subscales as it was
designed to tap three speciﬁc aspects of prostate cancer-
related anxiety, although the reliability of the ‘PSA anxi-
ety’ subscale was found to be weak in the original publi-
cation [3]. To our knowledge, the MAX-PC has never been
translated or used in an active surveillance setting [3–6].
Translation
The translation to Dutch followed standardized forward–
backward procedures [7]. First, three forward translations
by native Dutch with a medical background with ﬂuency in
English were performed and pooled into a common version
after a consensus meeting. Second, a native English
speaker ﬂuent in Dutch and also with a medical back-
ground translated this provisional Dutch version back into
English, while being blinded to the original version. This
back translation showed some discrepancies with the
source document, but these were mainly related to the
wording and not to the speciﬁc meaning of items. Con-
sensus was reached by discussion. The Dutch version of the
MAX-PC was ﬁrst tested face-to-face at the respondent’s
home in 5 participants, who completed the questionnaire
while thinking aloud in the presence of a researcher.
Afterward, guided by a checklist, potential problems in
acceptance or comprehension and time necessary for
questionnaire completion were explored and discussed with
the participant. Only minor problems, different for all 5
participants, were found during this process. These did not
indicate a need to adapt the Dutch version of the MAX-PC.
The Dutch version of the MAX-PC can be found
at https://www.prias-project.org/modules/news/article.php?
storyid=12.
Patients
Our study group consisted of Dutch patients who had been
recently diagnosed with prostate cancer, elected active
surveillance as the initial treatment option, and who con-
sented to participate in the prospective protocol-based
PRIAS (Prostate Cancer Research International: Active
Surveillance) study on active surveillance [8]. If diagnosed
between May 2007 and May 2008, these men received a
questionnaire within 6 months after diagnosis. Men are
medically eligible for the PRIAS study if they have small,
localized, and well-differentiated prostate cancer. The
medical ethics committee at the Erasmus University
Medical Centre in Rotterdam in The Netherlands (coordi-
nating centre) approved this study (number 2004-339).
Questionnaire
Besides the MAX-PC, the questionnaire included the
Decisional Conﬂict Scale (DCS, 16 items with 5 response
options: total score 0–100, with 100 indicating maximum
decisional conﬂict) to assess decisional conﬂict on the
choice for active surveillance [9]; the Centre for Epide-
miologic Studies Depression scale (CES-D, 20 items with
4 response options, total score 0–60, with 60 indicating
maximum depression) [10]; the abridged State Trait Anx-
iety Inventory (STAI-6, 6 items with 4 response options,
total score 20-80, with 80 indicating maximum generic
anxiety) [11]; and the Short Form health survey 12 (SF-12,
12 items with 2–6 response options, mean score 50, with a
standard deviation of 10 in the general US population) of
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score [12].
Quality criteria
Floor or ceiling effects causing an abnormal score distri-
bution were considered to be present when [15% of
respondents had the lowest or the highest possible score
[13].
We estimated the internal consistency by calculating the
Cronbach’s alpha coefﬁcients for the total MAX-PC and
the three subscales. An alpha of 0.7 is generally regarded as
sufﬁcient for group comparisons [14].
An initial conﬁrmatory factor analysis (CFA) model was
ﬁtted in which each item was assigned to one of the three
underlying factors, similar to the original publication, to
verify that the original factor structure was present in our
data [3]. Correlated factors were allowed in this model. The
ﬁt of the model was improved by freeing ﬁxed parameters
according to the sequence implied by the modiﬁcation
indices. When we found equal or nearly equal modiﬁcation
indices, priority was given to freeing ﬁxed parameters in
the covariance matrix of the errors over for instance ﬁxed
factor loadings [15]. Model ﬁt was assessed with the chi-
square (v
2) test, the root mean square error of approxima-
tion (RMSEA), and comparative ﬁt index (CFI).
Construct validity was assessed by comparing MAX-PC
total score and the three subscale scores with DCS, CES-D,
STAI-6, and SF-12 scores, respectively, using Pearson
correlation coefﬁcients. Correlations with r[0.3 were
considered relevant [16, 17]. We hypothesized that higher
scores on the total MAX-PC and subscales have to be
related to higher scores on DCS, CES-D, and STAI-6, and
to lower SF-12 MCS scores; that correlations were highest
with STAI-6, as this measure also is anxiety speciﬁc, and
lower with DCS, CES-D, and SF-12 MCS; and that cor-
relations with the ‘PSA anxiety’ subscale were lower,
because this is a very speciﬁc subscale, previously found to
show lower construct validity. We tested differences
between correlations with MAX-PC total for signiﬁcance
with a bootstrap procedure to obtain standard errors [18].
At least 75% of the results should be in accordance with
a priori hypotheses [13].
Statistical analysis
For statistical analysis, the commercially available soft-
ware Statistical Package for the Social Sciences, (version
15.0; SPSS, Inc, Chicago, IL, USA), S-Plus (version 8.0;
TIBCO software, Palo Alto, CA, USA), and LISREL
(version 8.72; Scientiﬁc Software International, Lincoln-
wood, IL, USA) [19] were used. A P-value of B0.05 was
considered statistically signiﬁcant.
Results
Out of the 150 questionnaires sent, 129 were completed at
a mean of 2.67 months (SD 1.74) after diagnosis (response
rate 86%). Patient characteristics are shown in Table 1, and
questionnaire scores and distributions are shown in
Table 2. All 129 men completed all 18 MAX-PC items. In
8 men, the DCS, CES-D, STAI-6, or SF-12 score were
discarded, as one or more items of one of these measures
were missing.
Only CES-D and the ‘PSA anxiety’ subscale showed
ﬂoor effects, with 25 and 85% of subjects exhibiting the
most favorable low score, respectively. No ceiling effects
were observed.
The Cronbach’s alpha coefﬁcients for the ‘prostate
cancer anxiety’ subscale, the ‘PSA anxiety’ subscale, the
‘fear of recurrence’ subscale, and the total MAX-PC were
0.91, 0.64, 0.85, and 0.77, respectively.
The initially ﬁtted CFA model in which the items were
assigned to the same factors as in the original publication
did not ﬁt very well (v
2 271.81 with 132 df, P\0.001,
RMSEA = 0.081, CFI 0.95). However, the modiﬁcation
indices in the sequence of subsequently ﬁtted models
Table 1 General, medical, and demographic patient characteristics
(N = 129)
General
Total number of patients 129
Mean age (year) (SD) 64.9 (6.9)
Mean time (months) between questionnaire completion
and diagnosis (SD)
2.7 (1.7)
Medical characteristics
Mean prostate-speciﬁc antigen level (ng/ml) (SD) 5.7 (1.9)
Clinical stage
T1C (%) 91 (71)
T2 (%) 38 (29)
Demographics
Education
Low (primary, secondary) (%) 86 (67)
High (college, university) (%) 42 (33)
Missing 1
Employed
Yes (%) 50 (60)
No (%) 76 (40)
Missing 3
Hospital
Academic/referral centre (%) 61 (47)
Other (%) 68 (53)
Marital status
Married/living together (%) 119 (92)
Other (%) 10 (8)
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freeing parameters in the error covariance matrix only,
while leaving the factor structure unchanged. Adding 10
extra covariance parameters among a total of 153 of these
parameters resulted in a just adequately ﬁtting model
(v
2 148.61 with 122 df, P = 0.051, RMSEA = 0.037, CFI
0.99) that had the same factor structure as the original.
These freed parameters indicated the presence of small
neglected factors. Table 3 presents the factor loadings and
standard deviations of the ﬁnal adequately ﬁtting CFA
model.
The correlation coefﬁcients of the MAX-PC scores with
DCS, CES-D, STAI-6, and SF-12 MCS are shown in
Table 4. The ‘PSA anxiety’ subscale did not show any
relevant correlations (r\0.3), while all other correlations
were [0.3. In line with prior hypotheses, the strongest
correlations of the MAX-PC and the three subscales were
seen with STAI-6. The P-value for the difference between
the correlation MAX-PC total—DCS (r = 0.41) and
MAX-PC total—CESD (r = 0.48) was 0.49, for MAX-PC
total—DCS (r = 0.41) versus MAX-PC total—STAI-6
(r = 0.66) P was 0.008. All other possible differences
between correlations were signiﬁcant at the 0.001 level.
Correlations were in line with hypotheses in[75%.
Discussion
We largely reproduced the structure and the validity of the
MAX-PC as a measure for prostate cancer-speciﬁc anxiety
in a sample of Dutch prostate cancer patients on active
surveillance. To our knowledge, no other questionnaires for
assessing prostate cancer-speciﬁc anxiety are available.
The ‘PSA anxiety’ subscale performed relatively poor
with a Cronbach’s alpha of 0.64 and with no relevant
correlations with other scores. These problems with the
‘PSA anxiety’ subscale were also observed in the original
version of the MAX-PC [3, 4]. The abnormal score dis-
tribution (85% of men in our population exhibited the
lowest possible score) limits the value of the ‘PSA anxiety’
subscale in our study.
Table 2 Questionnaire scores and distributions (N = 129)
Mean SD Median 25–75
Percentile
Possible
score range
Observed
score range
% Minimum
score
% Maximal
score
MAX-PC total 13.9 8.8 14.0 (6–20) 0–54 0–39 2 0
Prostate cancer anxiety 9.3 6.8 9.0 (3–14) 0–33 0–29 5 0
Prostate-speciﬁc antigen anxiety 0.3 1.0 0.0 (0–0) 0–9 0–6 85 0
Fear of recurrence 4.3 2.5 4.0 (2–6) 0–12 0–12 6 1
DCS 27.5 13.7 28.1 (18.8–36.3) 0–100 0–67.2 1 0
CES-D 5.7 6.1 4.0 (0.5–9.2) 0–60 0–24 25 0
STAI-6 35.9 9.0 35.0 (30–40) 20–80 20–66.7 5 0
SF-12 MCS 54.1 8.5 55.6 (52.2–60.1) Mean 50, SD 10 25.5–67.1 0 0
MAX-PC Memorial Anxiety scale-Prostate Cancer (prostate cancer-speciﬁc anxiety)
DCS Decisional Conﬂict Scale (decisional conﬂict)
CES-D Center for Epidemiologic Studies Depression scale (depression)
STAI-6 State Trait Anxiety Inventory-6 (generic anxiety)
SF-12 MCS Short-Form health-survey Mental Component Summary score (general mental health)
Table 3 Factor loadings (and standard deviations) in the ﬁnal ade-
quately ﬁtting conﬁrmatory factor analysis model
Subscales
Item Prostate cancer
anxiety
Prostate-speciﬁc
antigen anxiety
Fear of
recurrence
1 0.59 (0.07) – –
2 0.58 (0.07) – –
3 0.62 (0.07) – –
4 0.77 (0.07) – –
5 0.64 (0.07) – –
6 0.52 (0.06) – –
7 0.71 (0.07) – –
8 0.39 (0.06) – –
9 0.38 (0.06) – –
10 0.64 (0.08) – –
11 0.66 (0.06) – –
12 – 0.36 (0.06) –
13 – 0.14 (0.04) –
14 – 0.21 (0.05) –
15 – – 0.48 (0.07)
16 – – 0.48 (0.06)
17 – – 0.60 (0.06)
18 – – 0.67 (0.06)
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123Compared to the internal consistency scores reported in
other studies (alpha of the total MAX-PC 0.89-0.90; sub-
scales ‘prostate cancer anxiety’, ‘PSA anxiety’, and ‘fear of
recurrence’: 0.90–0.91, 0.54–0.64, and 0.82–0.85, respec-
tively [3–5]), Cronbach’s alpha for the total MAX-PC was
somewhat lower in our cohort but similar for the subscales.
CFA largely conﬁrmed the three-factor structure as used
in the original publication. Correlation analysis provided
evidence for the construct validity of the total score and the
‘prostate cancer anxiety’ and ‘fear of recurrence’ subscales
but not of the ‘PSA anxiety’ subscale. These ﬁndings are
also in line with results of the original version [3].
Our study has limitations. Future validation studies
should incorporate test–retest reliability, because this is an
important quality measure for questionnaires that have a
discriminative purpose such as the MAX-PC and longitu-
dinal validity. Second, our data lack any psychiatric
assessment or clinical diagnosis, so cut-off points for
clinical prostate cancer-speciﬁc anxiety could not be
established. Finally, we evaluated only a speciﬁc subgroup
of patients with prostate cancer, i.e. men who are on active
surveillance and who received the diagnosis no longer than
6 months earlier. As clinimetric properties may vary
between different study populations, it is recommended to
further validate the MAX-PC in other prostate cancer
patient cohorts, e.g. before and after surgery or radiation
therapy. Only with a multiple-group model or a direct
comparison with the original version of the MAX-PC, the
above-mentioned assertions on the validity of the Dutch
version of the MAX-PC can be conﬁrmed.
In conclusion, we found positive evidence for the
appropriateness of the MAX-PC to identify and quantify
prostate cancer-speciﬁc anxiety. It may allow for compar-
isons between Dutch patients and other international
observations and for comparisons of the effect of treat-
ments and/or supportive measures. However, some weak-
nesses in the original version, especially regarding the
‘PSA anxiety’ subscale, were also replicated in the adapted
Dutch version. The ‘PSA anxiety’ subscale of MAX-PC
may need to be revised.
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